TABLE II.

In-house questionnaire regarding symptoms, general well-being, treatment benefit, and treatment satisfaction after ILIT/SCIT 19 y earlier

Characteristic	ILIT	SCIT
Seasons with symptoms present
Spring (March-May)	19 (76)	22 (76)
Summer (June-August)	14 (56)	16 (55)
Autumn (September-November)	0 (0)	2 (7)
Winter (December-February)	1 (4)	4 (14)
All year	1 (4)	1 (4)
No symptoms	2 (8)	2 (7)
Nasal symptoms
Running nose	20 (80)	26 (90)
Loss of smell	2 (8)	2 (7)
Sneezing	24 (96)	24 (83)
Congestion	12 (48)	15 (52)
None	1 (4)	0 (0)
Eye symptoms
Itchy eyes	24 (96)	26 (93)
Red eyes	17 (68)	17 (61)
Puffy eyes	8 (32)	12 (43)
Watery eyes	10 (40)	17 (59)
None	1 (4)	0 (0)
General symptoms
Coughing	7 (28)	5 (18)
Dyspnea	7 (28)	6 (21)
Headache	2 (8)	5 (18)
Fatigue	7 (28)	11 (39)
None	12 (48)	14 (48)
Restrictions of daily life activities
Daily activities (at work/home)	2 (8)	2 (7)
Socializing	2 (8)	0 (0)
Outdoor activities	12 (48)	15 (54)
None	13 (52)	14 (48)
Mood affection by symptoms
I avoid company	2 (8)	0 (0)
I feel uncomfortable	5 (20)	7 (25)
I avoid leaving the house	3 (12)	5 (18)
I avoid activities	3 (12)	2 (7)
None	18 (72)	17 (59)
Invested time to follow treatment plan
A lot of time	3 (12)	14 (48)
A little of time	18 (72)	14 (48)
No effort	4 (16)	1 (4)
Usage of medication after finishing treatment
None	6 (24)	7 (24)
Antiallergics (maximum 1×/wk)	5 (20)	3 (10)
Antiallergics (>1×/wk)	11 (44)	8 (28)
Antiallergics daily	3 (12)	11 (38)
Medication type
Eye drops	12 (48)	18 (62)
Nasal sprays	6 (24)	15 (52)
Inhalers	6 (24)	8 (28)
Antiallergics (pills)	17 (68)	21 (72)
None	5 (20)	2 (7)
Treatment benefits
Long-term relief	4 (16)	3 (10)
Improvement	15 (60)	20 (69)
No improvement	4 (16)	6 (21)
Increase in symptoms	2 (8)	0 (0)
Treatment recommendation
Yes	19 (76)	23 (79)
No	6 (24)	6 (21)

Values are n (%).

Of note, several questions had more than 1 possible answer.